2024
Genomic and Immunophenotypic Characteristics of Conjunctival Squamous Cell Carcinoma in a Sub-Saharan African Cohort Suggest a Role for Immune Checkpoint Inhibitors in Locally Advanced or Metastatic Patients
Esmaeli B, Gleber-Netto F, Sagiv O, Pickering C, Gross N, Ning J, Yeshi M, Mitku Y, Nagarajan P. Genomic and Immunophenotypic Characteristics of Conjunctival Squamous Cell Carcinoma in a Sub-Saharan African Cohort Suggest a Role for Immune Checkpoint Inhibitors in Locally Advanced or Metastatic Patients. JCO Global Oncology 2024, 10: 85-86. DOI: 10.1200/go-24-72000.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsTumor mutational burdenConjunctival squamous cell carcinomaHigh-risk human papillomavirusSquamous cell carcinomaCheckpoint inhibitorsMetastatic patientsCell carcinomaImmunophenotypic characteristicsHigh risk human papillomavirus statusImmune checkpoint inhibitor therapyDensity of CD8+Sub-Saharan African cohortsPD-L1 expressionTumor-infiltrating lymphocytesCD3+ cellsTumors of patientsSub-Saharan AfricaWhole-exome sequencingSCC subtypePD-L1Thicker tumorsCD8+Clinical responseMutational burden
2022
Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma
Shi Y, Xie T, Wang B, Wang R, Cai Y, Yuan B, Gleber-Netto FO, Tian X, Rodriguez-Rosario AE, Osman AA, Wang J, Pickering CR, Ren X, Sikora AG, Myers JN, Rangel R. Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma. Communications Biology 2022, 5: 757. PMID: 35902768, PMCID: PMC9334280, DOI: 10.1038/s42003-022-03675-4.Peer-Reviewed Original ResearchConceptsOral cavity squamous cell carcinomaTumor immune microenvironmentCold tumor immune microenvironmentSquamous cell carcinomaICI therapyOSCC modelCell carcinomaImmune microenvironmentCold tumorsCell death protein 1 (PD-1) inhibitorsCancer cell-intrinsic mechanismsImmune checkpoint inhibitor therapyOral squamous cell carcinomaCheckpoint inhibitor therapyCombination ICI treatmentEffective immunotherapeutic approachesInterferon genes (STING) agonistImmunosuppressive M2 macrophagesProtein 1 inhibitorTobacco-associated cancersICI responsivenessICI treatmentCell-intrinsic mechanismsImmunotherapeutic approachesInhibitor therapy